Jazz Pharmaceuticals plc - SHS USD (JAZZ)

Historical Holders from Q1 2014 to Q3 2025

Symbol
JAZZ on Nasdaq
Type / Class
Equity / SHS USD
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares, excl. options
60.5M
Holdings value
$7.98B
% of all portfolios
0.013%
Grand Portfolio weight change
0%
Number of holders
494
Number of buys
214
Number of sells
-253
Average Value change %
0%
Average buys %
+0.003%
Average sells %
-0.004%
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Institutional Holders of Jazz Pharmaceuticals plc - SHS USD (JAZZ)

Period Reported Shares, Excl. Options Value, Excl. Options Change Price Investors
2025 Q3 60.5M $7.98B -$137M $131.80 494
2025 Q2 61.8M $6.56B +$172M $106.12 497
2025 Q1 60M $7.44B +$115M $124.15 545
2024 Q4 59M $7.27B +$148M $123.15 502
2024 Q3 57.6M $6.42B +$58.3M $111.41 469
2024 Q2 57.5M $6.13B -$38.4M $106.73 451
2024 Q1 57.7M $6.95B +$89.8M $120.42 475
2023 Q4 57.1M $7.02B -$57M $123.00 491
2023 Q3 56.5M $7.32B -$17.3M $129.44 482
2023 Q2 56.7M $7.04B -$22.1M $123.97 465
2023 Q1 56.7M $8.29B +$108M $146.33 462
2022 Q4 56.2M $8.95B -$100M $159.31 475
2022 Q3 56.9M $7.59B -$96.4M $133.29 443
2022 Q2 57.3M $8.93B +$138M $156.01 448
2022 Q1 56.7M $8.84B -$111M $155.67 437
2021 Q4 57.7M $7.35B +$21.4M $127.40 422
2021 Q3 56.9M $7.41B -$120M $130.21 422
2021 Q2 57.2M $10.2B +$781M $177.64 481
2021 Q1 53.1M $8.73B +$29.5M $164.37 435
2020 Q4 52.7M $8.69B -$295M $165.05 428
2020 Q3 54.5M $7.77B +$369M $142.59 382
2020 Q2 52.1M $5.74B +$270M $110.34 376
2020 Q1 49.8M $4.97B -$263M $99.74 397
2019 Q4 51.9M $7.74B +$163M $149.28 436
2019 Q3 51M $6.53B +$97.2M $128.14 397
2019 Q2 50.1M $7.13B +$207M $142.56 407
2019 Q1 51.4M $7.34B -$212M $142.95 415
2018 Q4 52.9M $6.55B -$427M $123.96 409
2018 Q3 55.4M $9.3B -$147M $168.13 397
2018 Q2 56.2M $9.67B +$436M $172.30 373
2018 Q1 53.7M $8.09B -$76.1M $150.99 320
2017 Q4 54.2M $7.3B -$66.7M $134.65 319
2017 Q3 54.6M $8B +$210M $146.25 299
2017 Q2 53.1M $8.26B +$375M $155.50 314
2017 Q1 52.3M $7.59B +$513M $145.13 302
2016 Q4 52.1M $5.68B -$159M $109.03 287
2016 Q3 53.4M $6.48B -$52.5M $121.48 317
2016 Q2 53.9M $7.61B -$43.5M $141.31 354
2016 Q1 54.6M $7.12B -$230M $130.55 330
2015 Q4 56.3M $7.91B -$16.8M $140.56 338
2015 Q3 56.4M $7.49B +$25.1M $132.81 350
2015 Q2 56M $9.86B +$620M $176.07 367
2015 Q1 52.5M $9.06B -$334M $172.79 352
2014 Q4 54.3M $8.89B +$176M $163.73 351
2014 Q3 53.2M $8.54B +$385M $160.56 320
2014 Q2 50.7M $7.46B +$45.6M $147.01 299
2014 Q1 50.5M $7B +$319M $138.68 310